National Multi-center Study Comparing Treatment Options for Mid-Low Rectal Cancer in China to Find the Best Approach

What this Trial Is About

This research aims to compare different treatment methods for mid-low rectal cancer across various medical centers in China. The study focuses on evaluating treatment effectiveness, patient outcomes, and the economic impact of these treatments. The goal is to identify the best treatment approach that meets the needs of different medical units and to provide evidence-based recommendations for medical quality control and clinical guidelines. Participants diagnosed with mid-low rectal adenocarcinoma, confirmed by pathology and located within 12 cm of the anal verge, are observed without specific interventions assigned by the study. This is a registry study collecting real-world data from multiple centers to analyze treatment practices and outcomes. The study will track patients over time to assess survival rates and other key clinical outcomes. Throughout the study, researchers will monitor several important outcomes, including 3-year overall survival, disease-free survival, local recurrence, and distant metastasis rates. They will also evaluate the use of neoadjuvant and adjuvant therapies, imaging assessments, surgical success rates, and mortality within 30 days after surgery. The study helps inform medical decisions and insurance planning by analyzing treatment costs and benefits based on real-world patient data.

Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer